M
Molecular Partners
Develops designed ankyrin repeat protein platform therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments
About Molecular Partners
Molecular Partners is a biopharmaceutical company focused on developing innovative therapies for cancer patients. Operating in the biotechnology sector, the company specializes in creating a new class of custom-built medicines designed to overcome the limitations of existing cancer treatments. Their core product line includes DARPin® therapeutics, which are engineered proteins that offer high specificity and potency. Molecular Partners primarily serves healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development, clinical trials, and partnerships with larger pharmaceutical firms for commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates. The company is committed to improving patient outcomes through collaborative and inclusive work practices, leveraging a diverse team of specialists to drive innovation.
Source: Dealroom company dataAt a glance
- Founded
- 2004
- Headquarters
- Zurich, Switzerland
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Molecular Partners.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Index Ventures
Johnson & Johnson- BVBB Biotech Ventures
Endeavour Vision
EW Healthcare Partners
Essex Woodlands Health Ventures
Series B and later6 investors entered at this stage
Suvretta Capital Management
Federated Hermes
BVF Partners- CMCamber Capital Management
Monashee Investment Management
HBM Healthcare Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
35 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Molecular Partners on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Molecular Partners on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.